Evidence map›Paper›PMID 35579820›Full record

ArticleDrug safety2022

Supervised Machine Learning-Based Decision Support for Signal Validation Classification.

Muhammad Imran, Aasia Bhatti, David M King, Magnus Lerch, Jürgen Dietrich, Guy Doron, Katrin Manlik

Abstract read
In one paragraph

Article in Drug safety, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Article
  2. Observational
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Muhammad ImranBayer AG, Digital Transformation and Information Technology Pharma, Decision Science and Advanced Analytics for Medical Affairs, Pharmacovigilance and Regulatory Affairs, Müllerstr. 178, 13353, Berlin, Germany. muhammad.imran5@bayer.com.ORCID http://orcid.org/0000-0002-4712-6634
Aasia BhattiBayer US LLC, Pharmaceuticals, Pharmacovigilance, Benefit-Risk Management TA Radiology, Whippany, NJ, USA.
David M KingBayer US LLC, Digital Transformation and Information Technology Pharma, Adverse Event Management, Morristown, NJ, USA.
Magnus LerchLenolution GmbH, Berlin, Germany.
Jürgen DietrichBayer AG, Pharmaceuticals, Pharmacovigilance, Innovation and Digitalization, Berlin, Germany.ORCID http://orcid.org/0000-0002-5494-3499
Guy DoronBayer AG, Pharmaceuticals, Pharmacovigilance, R&D, Data Sciences, Berlin, Germany.ORCID http://orcid.org/0000-0003-1252-5747
Katrin ManlikBayer AG, Pharmaceuticals, Pharmacovigilance, Data Science and Insight Generation, Berlin, Germany.ORCID http://orcid.org/0000-0003-3647-5326

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionSignal validation in pharmacovigilance is the process of evaluating data to decide whether evidence is sufficient to justify further assessment of a detected signal. During the signal validation process, safety experts in our organization are required to review signals of disproportionate reporting (SDRs) and classify them into one of six predefined categories.

objectiveThis experiment explored the extent to which predictive machine learning (ML) models can support the decision making of safety experts by accurately identifying the most appropriate predefined signal validation category.

methodsWe extracted cumulative data for six medicinal products, consisting of historic SDR validations and Individual Case Safety Reports, from the company's safety database for training and testing of the ML model. We implemented a decision tree-based supervised multiclass classifier model termed Gradient Boosted Trees followed by a SHapley Additive exPlanations (SHAP) analysis to mitigate the "black box" effect of the ensemble model by identifying the key predicting features in the model. Following a retrospective analysis, a prospective experiment was conducted to test the model accuracy and user acceptance in a real-life setting.

resultsThe prediction accuracy of our ML model ranged from 83 to 86% over 3 months for the six medicinal products. The applicability of the model was confirmed by the company's safety experts. Additionally, the systematic predictions provided valuable information to the safety experts and assisted them in reviewing the SDRs efficiently and consistently.

conclusionsThis experiment demonstrated that it is possible to train a multiclass classification model to accurately predict signal validation categories for SDRs. More importantly, the transparency of the predictions provided by the SHAP analysis led to high acceptance by the safety experts.

Indexed as

Machine LearningSupervised Machine LearningHumansPharmacovigilanceProspective StudiesRetrospective Studies

Identifiers

PMID35579820
PMCPMC9114067

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.